Thank you for joining us at the 5th Asian Conference on AIDS & Hepatitis on 28 and 29 May in Nanjing, China. We hope the conference was everything you hoped for and that you enjoyed your stay in Nanjing.
Once again, a special thank you to our sponsors: ViiV Healthcare, AbbVie and Gilead Sciences for their generous support that made this event possible.
Topics
Meeting category
Date(s)
20 May 2016 - 21 May 2016
Location
Shenzhen,
China
Organizer
Titanium Level Support
Sponsor logos
Asian Conference on Hepatitis and AIDS (ACHA) 2016
Related Enduring Materials
Enduring Materials
-
Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Chien-Ching Hung, MD, PhD
The study of anti HIV/AIDS in Nanjing
Clinical management of co-morbidities
Selecting the best ART for each patient
Eradication of HIV
Characterization of Hep B virus by ultra-deep sequencing and its clinical significance
Dr. XinXin Zhang
Shanghai Ruijin Hospital, China
Clinical cure of CHB: An intergration of antivirus and immune modulation
Dr. Qin Ning
Tongji Hospital, China
New Treatments/Targets in HBV
Victorian Infectious Diseases Reference Laboratory
RNAi therapeutics for chronic HBV - Animal models
RNAi therapeutics for chronic HBV - Clinical data
Early identification of HCV patients
Treatment of Hepatitis C: an Asian-Pacific perspective
Is HCV drug resistance an issue?
Anti viral hepatitis therapy for patients with liver transplantation
Comparing HIV guidelines around the world
NRTI backbone evolution of international HIV guideline update
National Taiwan University Hospital & National Taiwan University Hospital Yunlin Branch / National Taiwan University College of Medicine, Taiwan
Exploring the potential benefits of STRs features in the clinical management of HIV
The application of TLR4 antibodies in the treatment of liver failure
Dr. MaoRong Wang
The 81st PLA Hospital , China
Artificial liver therapy for hepatic failure
Clinical trial endpoints and trial design for Asia-Pacific region
Early treatment of HIV/ AIDS patients in China, 2012-2014: a retrospective observational cohort study
Overview
Welcome
General Information
Unique Features
- A program with a special focus on the needs in China and Asia
- A true scientific platform for local and regional clinicians and clinical researchers to present their data
- A unique opportunity for regional clinicians, researchers, and pharmaceutical companies to meet and collaborate
- A true scientific platform for local and regional clinicians and clinical researchers to present their data
- A unique opportunity for regional clinicians, researchers, and pharmaceutical companies to meet and collaborate
Who Should Attend?
- Clinicians and allied healthcare professionals involved in daily care of individuals infected with HBV, HCV, and HIV
- Scientists/researchers involved in antiviral drug development
- Post-graduate students
- Scientists/researchers involved in antiviral drug development
- Post-graduate students
Meeting Objectives
This meeting aims to:
- Provide education on the latest treatment options for HBV, HCV, HIV and associated co-infections
- Present the latest research data, especially in the Asian context and translate knowledge into clinical practice
- Provide a platform for interaction and dialogue among different disciplines and facilitate collaborations among local, national and regional communities
- Provide education on the latest treatment options for HBV, HCV, HIV and associated co-infections
- Present the latest research data, especially in the Asian context and translate knowledge into clinical practice
- Provide a platform for interaction and dialogue among different disciplines and facilitate collaborations among local, national and regional communities
Learning Objectives
After participating in this activity, participants will be able to:
- Summarize the most recent results in drug development (including most recent clinical trial results) for HBV, HCV, and HIV
- Integrate the latest scientific results into daily clinical care to improve the treatment quality for HBV, HCV and HIV-positive individuals
- Summarize the most recent results in drug development (including most recent clinical trial results) for HBV, HCV, and HIV
- Integrate the latest scientific results into daily clinical care to improve the treatment quality for HBV, HCV and HIV-positive individuals
Practical Information
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Support
Platinum Level
Endorsers
Language
Related Programs
